Solvay SA Considering Buying UCB Bioproducts

BRUSSELS (AFX) - Pharmaceutical group Solvay SA is considering buying peer UCB SA’s peptides unit UCB-Bioproducts, according to a source close to the company. The information is consistent with claims made in an earlier press report. ‘According to my information, the article in De Tijd is right, ' said the source. ‘The market is structured in such a way that all the players in that market will look at it,’ the source added. A company spokesman said that the group is ‘always looking at new opportunities’ -- declining to comment directly on the matter. Earlier, financial daily de Tijd, citing anonymous sources, said UCB is working on the sale of the unit, with peers Solvay, Bachem AG and Akzo Nobel NV in the frame for the deal. The newspaper said the unit would be worth 100 mln eur.

MORE ON THIS TOPIC